Farmas USA

Wall Street tiene la mejor semana en 7 años ¿ahora qué? Por Hugo Ferrer

https://inbestia.com/analisis/wall-street-tiene-la-mejor-semana-en-7-anos-ahora-que

CBIO

Catalyst Biosciences Announces Updated Positive Interim Data from Its Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors

http://ir.catalystbiosciences.com/news-releases/news-release-details/catalyst-biosciences-announces-updated-positive-interim-data-its

Miércoles 5 mercado cerrado. Dia nacional de luto por la muerte del expresidente Bush.

Sobre las presentaciones que van a hacer el domingo y lunes...

GlobeNewswire

NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( TGTX), today recapped the schedule of data presentations for the Company’s lead compounds, umbralisib (TGR-1202), the Company’s once-daily PI3K delta inhibitor, and ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, at the upcoming 60th American Society of Hematology (ASH) annual meeting and exposition, being held December 1-4, 2018, at the San Diego Convention Center.

Presentations at the ASH 2018 meeting include the following:

Oral Presentation Details:

• Title: Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation
  • Publication Number: 297
  • Oral Session: 642. CLL: Therapy, excluding Transplantation: Cellular Therapy and Immunomodulation in CLL
  • Session Date and Time: Sunday, December 2, 2018; 7:30 AM - 9:00 AM PT
    • Presentation Time: 8:00 AM PT
  • Location: Marriott Marquis San Diego Marina, Pacific Ballroom 20
  • Presenter: Anthony R. Mato, MD, Memorial Sloan-Kettering Cancer Center, New York, NY

Poster Presentation Details:

• Title: Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
  • Abstract Number: 4197
  • Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster III
  • Date and Time: Monday, December 3, 2018; 6:00 PM - 8:00 PM PT
  • Location: San Diego Convention Center, Hall GH
  • Presenter: Matthew A. Lunning, DO, University of Nebraska Medical Center, Omaha, NE

TGTX

China y USA 🇺🇸 acuerdan no poner más aranceles a partir de 01 Enero 2019
https://www.lavanguardia.com/internacional/20181202/453271724693/china-eeuu-guerra-comercial-aranceles-cumbre-g20-acuerdos.html

Entonces supongo que mañana tendremos fiestón generalizado. Espero que les dure mucho el tazón de all bran a estos dos y se queden calladitos por un tiempo.

Está a punto de explotar un escándalo por las prótesis de mama de Allergan, en las próximas semanas probablemente Francia emita comunicado de prohibición, voy a dar más detalles después, para informarme mejor, y ver si da para ponerse corto o no.

Una vez mas, Gracias Framus!

Estare a tento a TSRO. Gracias por la alerta. A ver si pasa a otra fase que genere un poco de calma.